Precision Cell Immunotherapy Combined With TACE in Advanced Liver Cancer

Summary

Objectives: To evaluate the safety and effectiveness of cell therapy using Precision Cells Combined With TACE in Advanced Liver Cancer. Eligibility: Individuals greater than or equal to 18 years of age and less than or equal to 65 years of age who have been diagnosed with Advanced Liver Cancer.

Timeline

Start

2016-08

Primary completion

2018-03

Completion

2018-08

Drugs

Indications